2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Gene Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3206 Targeting the IGF2BP3-UBR7-ACSL4 oncogenic axis reveals a precision therapeutic strategy for acute myeloid leukemia

Yaping Wang, Zhixiang Chen, MD2, Yuanhua Cai, MD, PhD3, Peiyao Wang4, wanting wu5, Yingying Zeng6, Yi Zheng7, Xiaolin Lai8, Qianglong Hong9, Xuechun Wang, MD10, Lin Xu, PhD11, Xiaofan Li Sr, MD, PhD12, Lili Pan13, Shaoyuan Wang14
1 Fujian Medical University Union Hospital, Fuzhou, China, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
2 Fujian Medical University Union Hospital, Fuzhou, China
3 Fujian Medical University Union Hospital, Fuzhou, China, Fujian Medical University Union Hospital, Fuzhou, China
4 Fujian Medical University Union Hospital, Fuzhou, China
5 Fujian Medical University Union Hospital, Fuzhou, China
6 Fujian Medical University Union Hospital, Fuzhou, China
7 Fujian Medical University Union Hospital, Fuzhou, China
8 Fujian Medical University Union Hospital, Fuzhou, China
9 Fujian Medical University Union Hospital, Fuzhou, China
10 Fujian Medical University Union Hospital, Fuzhou, China
11 Fujian Medical University Union Hospital, Fuzhou, China
12 Fujian Medical University Union Hospital, Fuzhou, China
13 Fujian Medical University Union Hospital, Fuzhou, China
14 Fujian Medical University Union Hospital, Fuzhou, China

The m6A reader IGF2BP3 is frequently overexpressed in AML and promotes leukemogenesis, yet the critical downstream effectors mediating its oncogenic functions and the therapeutic opportunities they present remain undefined.

To address this gap, we first evaluated IGF2BP3 in a cohort of 92 AML patients and 29 healthy controls. IGF2BP3 was markedly elevated versus healthy controls (AUC=0.822, 95% CI 0.74–0.91), and high expression independently predicted shorter overall survival (P=0.0012) and was associated with adverse features including older age, higher marrow blasts, and lower hemoglobin. In xenografts, IGF2BP3 overexpression accelerated leukemia progression (median survival 25 vs. 32 days, P=0.0008), while knockdown extended survival (49 vs. 33 days, P=0.0027). Integrating MeRIP-seq and RNA-seq identified UBR7 as a high-confidence m6A-dependent target. IGF2BP3 bound directly to m6A-modified UBR7 transcripts via its KH3–4 domains, stabilizing UBR7 mRNA (5.14±0.74-fold reporter activation). UBR7 knockdown extended xenograft survival (33 vs. 30 days, P=0.019), and its overexpression partially reversed the anti-proliferative and pro-apoptotic effects of IGF2BP3 depletion, establishing UBR7 as a critical functional mediator.

To define the downstream mechanism, we integrated transcriptomic and ChIP-seq analyses and identified ACSL4 as a direct transcriptional target of UBR7 via dual luciferase reporter assays. ACSL4 was essential for AML cell survival, as its knockdown inhibited proliferation and induced apoptosis, while overexpression promoted leukemic growth in vitro and in vivo (P<0.01). Recognizing ACSL4 as a druggable enzyme, we evaluated rosiglitazone, an FDA-approved antidiabetic agent whose safety and pharmacokinetics are well-characterized in humans. Computational docking predicted favorable ACSL4 binding (−7.9 kcal/mol). Notably, rosiglitazone treatment reduced ACSL4 protein levels in a dose-dependent manner. This corresponded to selective suppression of proliferation and induction of apoptosis in IGF2BP3-overexpressing AML lines and primary samples (significant at 10 μM, a clinically achievable concentration), with minimal effects on normal hematopoietic cells. The specificity of this effect was confirmed using PRGL493, another ACSL4 inhibitor, which phenocopied rosiglitazone's anti-leukemic activity. In xenograft models bearing IGF2BP3-overexpressing AML, rosiglitazone (50 mg/kg/day) was well-tolerated with no significant hepatotoxicity or hypoglycemia, significantly reduced tumor burden (P<0.05) and prolonged overall survival (31 vs. 28 days, P=0.0224), with survival in treated mice comparable to control xenografts.

Collectively, these findings uncover a m6A-dependent IGF2BP3–UBR7–ACSL4 oncogenic axis driving AML and demonstrate that pharmacological ACSL4 inhibition by rosiglitazone selectively targets this pathway, representing a promising repurposing strategy for AML patients with high IGF2BP3 expression. Our results provide a strong mechanistic and preclinical rationale for clinical evaluation of rosiglitazone in this biomarker-defined adverse prognostic subgroup.

Yaping Wang: No relevant conflicts of interest to declare.